Nicholas C. Kallan
Array BioPharma (United States)(US)Chugai Pharma (United States)(US)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Biochemical and Molecular Research, Alzheimer's disease research and treatments, Protein Kinase Regulation and GTPase Signaling, Computational Drug Discovery Methods
Most-Cited Works
- → Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors(2012)184 cited
- → Synthesis of the Ring System of Phomactin D Using a Suzuki Macrocyclization(2000)80 cited
- → Spirocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: From Hit to Lowering of Cerebrospinal Fluid (CSF) Amyloid β in a Higher Species(2013)58 cited
- → A potential therapeutic target for FLT3-ITD AML: PIM1 kinase(2011)56 cited
- → Discovery of pyrrolopyrimidine inhibitors of Akt(2010)55 cited
- → Discovery and SAR of spirochromane Akt inhibitors(2011)42 cited
- → Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors(2010)37 cited
- → Discovery of a Novel Class of Imidazo[1,2-a]Pyridines with Potent PDGFR Activity and Oral Bioavailability(2013)28 cited
- → Synthesis of Akt Inhibitor Ipatasertib. Part 1. Route Scouting and Early Process Development of a Challenging Cyclopentylpyrimidine Intermediate(2014)13 cited
- → Elucidating the Mechanism of Cytochrome P450–Mediated Pyrimidine Ring Conversion to Pyrazole Metabolites with the BACE1 Inhibitor GNE-892 in Rats(2014)12 cited